The directors of the Irish arm of pharma giant Roche have stated that there is a need to reduce the lengthy timelines to ...
Irish Examiner on MSN1d
Profits at Irish arm of Roche pharma climb by 17%Latest news on Ireland's companies and busines organisations and their impact locally, nationally and globally.
RHHBY records impressive sales growth in 2024 on the back of strong demand for Vabysmo, Hemlibra, Phesgo and Ocrevus.
Swiss pharma giant Roche Holding AG RHHBY posted better-than-expected 2024 results and provided an encouraging outlook for 2025. Sales in 2024 totaled $68.7 billion, which beat the Zacks Consensus ...
Group sales grew by 7%1 at constant exchange rates (CER; 3% in CHF), driven by strong demand for both medicines and diagnostics.Excluding COVID-19, Group sales increased by 9%.
Its biosimilar of Roche’s cancer and autoimmune disease drug MabThera (rituximab) is already on sale in Germany under the brand name Truxima. But the South Korean company has received the go ...
That changed with the next two biosimilars to come online, which were versions of the cancer drugs MabThera (rituximab) and Herceptin (trastuzumab). This time around incentives were put in place ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback